Oncology Topic Homepage

Prostate Cancer Learning Hub

,Prostate Cancer Learning Hub

Prostate cancer is the third most frequently diagnosed cancer in Europe and the most common cancer among European men,1 making it a major cause of morbidity. Risk factors for prostate cancer include, increasing age, genetic susceptibility, glucose intolerance and environmental factors.2

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer.

The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer. In addition access to editorials of key journal publications, an events calendar, video channel, patient materials and interactive healthcare professionals tools are also available.

References

  1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403. EUCAN fact sheet. Estimated incidence, mortality & prevalence, 2012.
  2. Tewari R, Rajender S, Natu SM et al. Diet, obesity, and prostate health: are we missing the link? J Androl 2012;33:763-776.

     

Soft Tissue Sarcoma

Soft Tissue Sarcoma

Soft Tissue Sarcomas (STS) are malignant (cancerous) tumors that develop in tissues which connect, support, or surround other structures and organs of the body. Muscles, tendons (bands of fiber that connect muscles to bones), fibrous tissues, fat, blood vessels, nerves, and synovial tissues are types of soft tissue.

Management of soft tissue sarcoma depends on the stage of disease and histological subtype.1 Surgery is the mainstay of treatment for patients with localised disease and is often curative. However, as recurrence is likely to occur when tumour cells remain after surgery, adjuvant radiotherapy is often also considered, especially for patients with intermediate or high-grade tumours. Radiotherapy, uses high energy rays to help cure cancers, is also often administered for patients in whom surgery is inappropriate or who decline surgery.1

For soft tissue sarcomas, the specialist healthcare professional may recommend radiotherapy to shrink sarcomas before surgery, help stop the sarcoma returning after surgery, to help slow the growth rate of advanced sarcomas and help relieve symptoms.

Discover classification of sarcomas by histopathology, look at prevalence and more by visiting the The Soft Tissue Sarcoma Knowledge Centre.


References

  1. . Clark MA, Fisher C et al. (2005) “Soft-tissue sarcomas in adults.” N Engl JMed 353(7): 701–11.

Clinical Case Studies

Sarcoidosis (Radiographic Stage I)

Respiratory Medicine & Allergy: Non granuloma interstitial lung disease

Anne Collett, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Richard Leach, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK

Case History
A 35-year-old male Caucasian barrister presented with a four-week history of dry cough, breathlessness and fatigue. There was no past medical history.

Amiodarone Pulmonary Toxicity

Respiratory Medicine & Allergy: Non granuloma interstitial lung disease

Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK
Boris Lams, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Christopher Kosky, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London , UK

Case History
A 72-year-old woman presented to hospital with shortness of breath. Two years prior to presentation she had been commenced on amiodarone 200 mg a day for non-sustained ventricular tachycardia.

Medical Videos

Eribulin Trial Success
Eribulin Trial Success
An Overview of Pancreatic NET and the Available Treatments
An Overview of Pancreatic NET and the Available Treatments
In the podcast, Dr. Crawford describes current and upcoming options available to urologists for treating this group of patients.
In the podcast, Dr. Crawford describes current and upcoming options available to urologists for treating this group of patients.
Surviving Advanced Breast Cancer
Surviving Advanced Breast Cancer
Metastatic Breast Cancer - A Patient's View of Various Treatments Including Eribulin
Metastatic Breast Cancer - A Patient's View of Various Treatments Including Eribulin
New Developments in the Treatment of Breast Cancer
New Developments in the Treatment of Breast Cancer
Cancer Vaccines- Dr. Kelvin Lee
Cancer Vaccines- Dr. Kelvin Lee
An Animation Explaining the Development of Lymphoma
An Animation Explaining the Development of Lymphoma
HPV Vaccine
HPV Vaccine

Recent Drug Updates

Medical Journal Abstracts on Oncology

Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity

8 days ago -  BJU International

PurposeTo evaluate whether a history of smoking or smoking during therapy after external beam radiotherapy EBRT for clinically localized prostate cancer is associated with increased ...

The outcome of cryoablation in treating advanced pancreatic cancer: A comparison with palliative bypass surgery alone

Thu 16 Oct 2014 -  Journal of Digestive Diseases

ObjectiveThis study aimed to investigate the efficacy and safety of palliative bypass surgery combined with cryoablation in treating patients with advanced pancreatic cancer and compare this ...

Medical Images

Pulmonary nodule
Pulmonary nodule
Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Amiodarone Pulmonary Toxicity
Amiodarone Pulmonary Toxicity
Sarcoidosis - chest radiograph
Sarcoidosis - chest radiograph
Bronchogenic cyst
Bronchogenic cyst
Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer (SCLC)
Hypersensitivity Pneumonitis
Hypersensitivity Pneumonitis
Sarcoidosis - radiograph showing interstitial shadowing
Sarcoidosis - radiograph showing interstitial shadowing
Hematoxylin and eosin stain
Hematoxylin and eosin stain

Online CME

No Blunting of Immunologic Response to Sipuleucel-T When Combined With Abiraterone Acetate Plus Prednisone in mCRPC

After participating in this activity, clinicians should be better able to: Describe the differences in immunologic end points between concurrent sipuleucel-T and abiraterone as compared with the sequential use of...

mCRPC: The Right Treatment for the Right Patient at the Right Time

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists and urologists involved in the treatment of patients with metastatic prostate cancer. The goal of...

Clinical Review - Acoustic neuroma

This activity covers the diagnosis and management of acoustic neuroma.

Clinical Trials

OSCA - Olaparib Standard of CAre Study

06-10-2014

This study will be carried out as a retrospective, non-interventional observational review of medical records for patients in multiple countries with platinum-sensitive recurrent serous ovarian cancer. The objectives are to describe in a real-world..

... population, treatment patterns, BRCA mutation testing and results, overall survival, health care utilization and also to estimate rates of selected treatment- and/or disease-related side effects

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

02-10-2014

This study is a multicenter, open-label study of polatuzumab vedotin administere d by intravenous (IV) infusion in combination with standard doses of bendamustin e (B) and rituximab (R) or obinutuzumab (G) in patients with relapsed or refract ory..

... follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase 1b dose-escalation stage and a Phase 2 stage. The anticipated time on treatment is 18-24 weeks.

Back to top